Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Ayvens Responds to FCA Consultation on Motor Finance Redress Scheme
- Anthropic's Claude 4.5: New Discoveries in AI Testing Awareness
- Nvidia and Intel Forge New Alliance for Future Success
- Billionaire Investors Boost Nvidia Holdings Amid High Hopes
- Huhtamaki Announces Q3 2025 Interim Report Release Plans
- Huhtamaki's Upcoming Q3 Interim Report and Insights
- Revolutionizing Customer Engagement with AI at Apivia Courtage
- Cornish Metals Moves Forward with UK Re-Domiciling Plans
- NB Private Equity Partners Enhances Share Buyback Strategy
- Kenmare Resources Enhances Wet Concentrator Plant A Capabilities
- Foresight Group's Strategic Share Buyback Program Unveiled
- AS Ekspress Grupp Announces Significant Board Changes Ahead
- Francesco Ciancia Appointed as Global Head of Manufacturing
- Aeson Power Unveils Innovative Energy Solutions at Expo
- Empowered Living: Ultimate Performance's Campaign for Women's Health
- AidenAI Secures Spot as HFS Hot Tech Vendors 2025
- Exploring AI and Cybersecurity Collaboration Through Tuya Smart
- Stellantis Announces Leadership Changes to Drive Future Success
- Surging Growth of the 4K TV Market Unveiled for Future
- Celebrating Excellence: The 2025 Fintech Innovation Awards
- Cregis Showcases Blockchain Solutions at FOREX Expo 2025
- Cregis Pioneers Blockchain Adoption at Asia's Leading Event
- Levi Strauss Prepares for Q3 Earnings: Key Analyst Updates
- Performance Brokerage Facilitates Transition of Freedom Harley-Davidson
- Sampo plc Reports Significant Share Buybacks for October 2025
- Umicore's Strategic Move to Unlock Value from Gold Inventories
- ONWARD Medical Gains Buy Rating from BNP Paribas Group as Growth Accelerates
- FLSmidth's Share Buy-Back: Insightful Transaction Updates
- Steve Hanke Critiques Bitcoin's Rally Amid Federal Uncertainty
- Oncoinvent's Radspherin Shows Promise in Ovarian Cancer Treatment
- Oncoinvent's Radspherin® Trials Show Promise for Ovarian Cancer
- Expert Opinions on Tesla's Recent Vehicle Pricing Strategy
- Market Dynamics Shift: S&P 500 Falls, Investors Remain Watchful
- Transforming Visual Programming: TopLineSoft's Innovative Approach
- Teck Resources Provides Update on Operations and Production Outlook
- AlphaMedix™ Demonstrates Promising Efficacy in Neuroendocrine Tumors
- AlphaMedix Progresses in Phase 2 Study for Neuroendocrine Tumors
- TGS ASA Q3 2025 Update: Strong Performance and Future Outlook
- Mica Dolan Takes the Helm as ATI's New CEO
- RadCred Revolutionizes Bad Credit Emergency Loans in 2025
- Dubai's Summit 2025: Shaping Tomorrow's Publishing World
- AlphaMedixTM Shows Promise in Phase 2 Study for GEP-NETs
- Top Stocks to Monitor as Market Trends Shift on Wednesday
- RadCred Innovates Emergency Loans for Bad Credit Access
- DNPA Partners with Magnite for Enhanced Advertising Solutions
- Nuburu Inc. Secures Strategic Acquisition Boosting Shares
- Dan Ives Promotes Vision of Eightco Holdings and World Network
- Hepsor Launches Innovative Bond Program for Future Growth
- Peter Schiff Encourages Gold Miners as Prices Surge Steadily
- Strategic Education Partnership: Fostering Advanced Learning in Pakistan